EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

Swetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera iD, Matthew Mei iD, Liana Nikolaenko, Xiaofang Zuo, Shen Yin, Mingzhu Zhou, Yong Mun, Mei Wu, Michael C Wei, Lihua E Budde iD

British Journal of Haematology · 2026-01 · 208 (1) · 149-158

DOI: 10.1111/bjh.70212 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 18.11.2025. Verfasst von Swetha Kambhampati Thiruvengadam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, Inc., Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102;

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansAgedFemaleMaleMiddle AgedAged, 80 and overAdultAge FactorsRecurrenceTreatment Outcome

Stichwörter der Autor:innen

antibody therapyelderlyhaematological malignanciesnon‐Hodgkin lymphoma

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.
  • Hematology and Blood and marrow Transplant, City of Hope Cancer Center, Atlanda, George, USA.
  • Genentech, Inc., South San Francisco, California, USA.
  • F. Hoffmann-La Roche Ltd, Shanghai, China.

ORCID-Profile: Alex F Herrera, Matthew Mei, Lihua E Budde

Förderung

  • Genentech, Inc.
  • Genentech

Zitieren

APA

Thiruvengadam, S. K., Popplewell, L. L., Herrera, A. F., Mei, M., Nikolaenko, L., Zuo, X., Yin, S., Zhou, M., Mun, Y., Wu, M., Wei, M. C., & Budde, L. E. (2026). Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study. British Journal of Haematology, 208(1), 149-158. https://doi.org/10.1111/bjh.70212

Vancouver

Thiruvengadam SK, Popplewell LL, Herrera AF, Mei M, Nikolaenko L, Zuo X, et al. Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study. British Journal of Haematology. 2026;208(1):149-158. doi:10.1111/bjh.70212

BibTeX
@article{Thiruvengadam2026,
  author = {Thiruvengadam, Swetha Kambhampati and Popplewell, Leslie L and Herrera, Alex F and Mei, Matthew and Nikolaenko, Liana and Zuo, Xiaofang and Yin, Shen and Zhou, Mingzhu and Mun, Yong and Wu, Mei and Wei, Michael C and Budde, Lihua E},
  title = {Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {1},
  pages = {149--158},
  doi = {10.1111/bjh.70212}
}
Kostenlos starten →